Galmed Pharmaceuticals Ltd.
EOCN Nasdaq· Pharmaceutical Preparations
Last close · Oct 30, 2026
$3.10
KIRA · Stoqly’s AI analyst, in plain words
- Galmed Pharmaceuticals Ltd. lost $10.3M in fiscal 2025.
- Operating cash flow was −$6.3M in fiscal 2025. At that burn of $6.3M a year, its $8.8M of cash and short-term investments would last about 1.4 years.
Market cap
$3.0M
P/E
1.3x
Revenue
—
Net income
−$10.3M
Free cash flow
—
Operating margin
—
Galmed Pharmaceuticals Ltd. in 30 seconds · fiscal 2025
Does it make a profit?
−$10.3M
No. It lost money last year.
How long would its cash last?
1.4 yrs
For now. It burns $6.3M a year and holds $8.8M, about 1.4 years at that pace.
How is the share priced?
1.3x
One share costs 1.3 times its yearly profit per share.
What Galmed Pharmaceuticals Ltd. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 31, 2026
- Legal name
- Galmed Pharmaceuticals Ltd.
- CIK
- 0001595353
Galmed Pharmaceuticals Ltd. · EOCN · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$32.5M | −$17.9M | −$6.9M | −$7.5M | −$10.3M |
| Diluted EPS | $19.80 | $127.80 | $30.00 | $8.08 | $2.39 |
| Cash | |||||
| Cash from operations | −$32.9M | −$18.5M | −$6.1M | −$5.9M | −$6.3M |
| Capital expenditure | $0.0M | $0.0M | — | — | — |
| Free cash flow | −$32.9M | −$18.5M | — | — | — |
| Share count change | −92.3% | −91.5% | 65.2% | 303.3% | 363.2% |
| Debt and strength | |||||
| Cash and short-term investments | $34.8M | $13.8M | $10.4M | $11.9M | $11.0M |
| Shareholders' equity | $30.5M | $13.4M | $13.9M | $16.3M | $15.8M |
| Current ratio | 6.1x | 4.8x | 4.8x | 7.4x | 6.5x |
| Returns and quality | |||||
| Return on equity | −87.0% | −81.4% | −50.6% | −49.8% | −64.2% |
| Return on tangible equity | −106.5% | −133.1% | −49.8% | −46.0% | −65.3% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Galmed Pharmaceuticals Ltd. · EOCN · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.10 a share, the company is worth $3.0M: 1.3 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001595353). Latest version: stoqly.net/companies/eocn. Data updated November 1, 2026. For information only — not investment advice. Check the original filings before relying on any figure.